{"path":"Images/Pasted image 20231024150812.png","text":"NCS-related l e ok bighbodng kNS { ) v B é | thrombotic risk v — | Ry v Y (o (e JERERIEE) Continue with INR b - (Ca) inlower level or | | Short interruption® short interruption (Class Iy Bridging i (Cimss) e — — (Class I Bridging is not. Bridging is not recommended recommended (Class Il (Class ) @Esc Figure 8 Recommendations for management of oral anticoagulation therapy in patients undergoing non-cardiac surgery. CHA;DS,-VASc, congestive heart failure, hypertension, age >75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, sex category (female); N, no; NCS, non-cardiac surgery; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist; VTE, venous thromboembolism. Y, yes; Mechanical aortic valve replacement (AVR) and any thromboembolic risk factor (atrial fibrillation, previous thromboembolism, severe left ventricular dysfunction, hypercoagul- able state), or older-generation mechanical AVR, or a mechanical mitral valve replacement. *Recent stroke <3 months, high risk of VTE recurrences (e.g. antithrombin 3 deficiency or protein C and/or S deficiency), left ventricular apex thrombus, atrial fibrillation with a very high stroke risk. “Bridging with unfractionated heparin or low molecular weight heparin. “Eg. >3 months after stroke/VTE. *For NOAC management during NCS, see Figures 9 and 10.","libVersion":"0.3.2","langs":"eng"}